Feldan is the leading company engaged in the discovery, development, manufacturing and marketing of research & therapeutic protein products and services.

The company is known for its capacity to develop and manufacture novel and challenging proteins.

The company markets products and services to the life science industry mainly in the US, Canada and Europe; but also markets in other countries across the globe through its marketing force.

The company's innovation pipeline currently focuses on research areas that target treatment of serious illness in areas such as oncology, immunology, neuroscience, inflammation and stem cell therapy.

Feldan is organized around two main business segments - Research Proteins and Therapeutic Proteins.

THE RESEARCH PROTEIN SEGMENT of the company discovers, develops, manufactures, and markets one of the world's broadest and most diversified research portfolios and custom protein-related services. It possesses leadership in virtually all key high-growth research areas.

In addition, the company also manufactures and markets hundreds of molecular biology kits used to isolate, manipulate and amplify DNA.

Feldan's primary research target market includes universities and medical institutions, contract manufacturing organizations, life science companies, government agencies, pharmaceuticals manufacturers and biotechnology research organizations.

THE THERAPEUTIC PROTEIN SEGMENT of the company develops and licenses therapeutic proteins that are the generic equivalent of brand biopharmaceuticals that no longer enjoy patent protection.

Feldan's primary therapeutic target market includes biotech industry newcomers looking to locally manufacture and commercialize high-quality biopharmaceuticals for the treatment of various diseases including cancer, diabetes, hepatitis or multiple sclerosis.